Ambica: Creating a healthier Philippines
MANILA, Philippines - “To protect the health of American citizens, the United States Food and Drug Administration (USFDA) upholds the strictest and highest quality standards for pharmaceutical products . . . the fact that the US is the biggest buyer of medicines from India is best proof of the quality and safety of India’s pharma products. These are the same medicines that are now being made available to budget-conscious Filipinos at very affordable prices, often several times lower than the price of multinational brands,” says Kamal Abichandani, president of Ambica International Trading Corp., one of the main distributors of Indian pharmaceuticals/medicines in the Philippines. “I hope this puts to rest the totally false allegations made by certain parties that low-priced Indian medicines are unsafe and ineffective. Apparently, they are trying to scare people into buying overpriced drugs just to protect their business profits, regardless of the impact on people’s lives, especially the poor who can hardly afford to buy food, much less medicines.”
In the Philippines, Ambica has been the main distributor of pharma products from these companies for nearly 15 years. “By making these affordable world-class medicines from India available even to low-income Filipinos, Ambica is living up to its central mission, which is to help create a healthier Philippines,” notes S. Suresh Kumar, Ambica’s vice president for marketing and sales. “Our main divisions, such as the Cardiovascular and Metabolic Division, Oncology Division, Biotechnology Division, Dermatology and Hospital Division, and Pharma Distribution Division are all working towards this central mission.”
For more information on top quality, safe, and affordable medicines approved by USFDA and RP-FDA, visit the Ambica website at www.ambicaphilippines.com; call 828-6617 to 18; 828-6542; fax 828-6615; text or call mobile 09175546073, 0917554-6072; e-mail kamal@ambicaphilippines.com, suresh.kumar@ambicaphilippines.com, smhp07@gmail.com.